Intellia Therapeutics Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Intellia Therapeutics de 33.4% y 58.3% por año respectivamente. Se prevé que el BPA crezca en un 37.6% al año. Se espera que la rentabilidad financiera sea de -15.6% en 3 años.

Información clave

33.3%

Tasa de crecimiento de los beneficios

37.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	25.7%
Tasa de crecimiento de los ingresos	58.6%
Rentabilidad financiera futura	-45.6%
Cobertura de analistas	Good
Última actualización	16 Jul 2024

Actualizaciones recientes sobre el crecimiento futuro

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 24

Recent updates

Here's Why It's Unlikely That Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO Will See A Pay Rise This Year

Jun 06

Intellia Therapeutics Presents Promising In Vivo CRISPR Results

Jun 05

Industry Analysts Just Made A Dazzling Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts

May 14

Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies

May 13

Intellia Therapeutics Is On The Move

Feb 29

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 24

Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier

Feb 09

Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?

Feb 07

Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?

Jan 01

Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans

Oct 20

Intellia Therapeutics: Top Speculative Trade In The Biotech Space

Oct 05

Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling

Sep 01

Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022

Feb 09

Intellia: Best All-Around Gene Editing Company

Jan 27

We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth

Dec 31

Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans

Dec 15

Intellia Stock: Setting Up For Success

Nov 29

Intellia: A Step Closer To A Life-Changing Cure

Nov 21

Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Intrinsic Value Is Potentially 79% Above Its Share Price

Oct 11

Intellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon

Aug 31

Here's Why We're Not At All Concerned With Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation

Aug 01

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:NTLA - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	116	-557	-426	-216	17
12/31/2025	60	-532	-414	-357	27
12/31/2024	69	-489	-384	-364	27
3/31/2024	53	-486	-418	-405	N/A
12/31/2023	36	-481	-408	-394	N/A
9/30/2023	52	-462	-407	-391	N/A
6/30/2023	53	-453	-384	-368	N/A
3/31/2023	53	-430	-379	-363	N/A
12/31/2022	52	-474	-392	-333	N/A
9/30/2022	51	-442	-355	-298	N/A
6/30/2022	45	-400	-342	-285	N/A
3/31/2022	38	-369	-309	-252	N/A
12/31/2021	33	-268	-238	-225	N/A
9/30/2021	27	-229	-221	-211	N/A
6/30/2021	42	-185	-181	-174	N/A
3/31/2021	52	-149	-69	-64	N/A
12/31/2020	58	-134	-53	-50	N/A
9/30/2020	62	-120	-43	-38	N/A
6/30/2020	51	-116	-41	-35	N/A
3/31/2020	46	-109	-126	-120	N/A
12/31/2019	43	-100	-110	-103	N/A
9/30/2019	40	-90	-89	-83	N/A
6/30/2019	37	-89	-76	-70	N/A
3/31/2019	33	-86	-71	-65	N/A
12/31/2018	30	-85	-68	-61	N/A
9/30/2018	29	-90	-81	-74	N/A
6/30/2018	29	-83	-86	-78	N/A
3/31/2018	27	-76	-79	-72	N/A
12/31/2017	26	-68	N/A	-65	N/A
9/30/2017	25	-54	N/A	-58	N/A
6/30/2017	23	-46	N/A	-49	N/A
3/31/2017	21	-38	N/A	34	N/A
12/31/2016	16	-32	N/A	36	N/A
9/30/2016	13	-26	N/A	45	N/A
6/30/2016	9	-22	N/A	49	N/A
3/31/2016	7	-18	N/A	-16	N/A
12/31/2015	6	-12	N/A	-2	N/A
9/30/2015	4	-14	N/A	1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que NTLA siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que NTLA siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que NTLA siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (58.3% al año) de NTLA crezcan más rápidamente que los del mercado US (8.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (58.3% al año) de NTLA crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: NTLA se prevé que no sea rentable en 3 años.

Intellia Therapeutics Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Price target decreased by 7.1% to US$96.27

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to US$137

Price target decreased to US$155

Recent updates

Blueallele Corporation Files Lawsuit for Patent Infringement Against Intellia Therapeutics, Inc., for the Unauthorized Use of Blueallele’S Patented Bi-Directional Insertion Templates

Intellia Therapeutics, Inc. Announces Chief Financial Officer Changes

Intellia Therapeutics, Inc. Announces Chief Financial Officer Changes

Intellia Therapeutics to Present the First-Ever Clinical Data from Patients Redosed with an Investigational in Vivo CRISPR Gene Editing Therapy At the Peripheral Nerve Society Annual Meeting 2024

Intellia Therapeutics, Inc. Names Brian Goff to its Board of Directors

Here's Why It's Unlikely That Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO Will See A Pay Rise This Year

Intellia Therapeutics Presents Promising In Vivo CRISPR Results

Intellia Therapeutics, Inc. Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002

Industry Analysts Just Made A Dazzling Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts

Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies

First quarter 2024 earnings released: US$1.13 loss per share (vs US$1.18 loss in 1Q 2023)

Intellia Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Intellia Therapeutics, Inc., Annual General Meeting, Jun 12, 2024

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

Intellia Therapeutics Is On The Move

Intellia Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $375.727167 million.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

New major risk - Revenue and earnings growth

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier

Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

President recently sold US$566k worth of stock

Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?

Independent Director notifies of intention to sell stock

Intellia Therapeutics, Inc. Announces Resignation of John F. Crowley from the Board of Directors of Company and Its Committees

Third quarter 2023 earnings: EPS exceeds analyst expectations

Intellia Therapeutics, Inc. Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 At the 4th International ATTR Amyloidosis Meeting

Insufficient new directors

Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Intellia Therapeutics, Inc. Appoints Eliana Clark, Phd, Executive Vice President and Chief Technical Officer

Intellia Therapeutics, Inc. Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Announces Resignation of Jean-François Formela as Board Member

First quarter 2023 earnings released: US$1.18 loss per share (vs US$1.97 loss in 1Q 2022)

Price target decreased by 7.1% to US$96.27

Full year 2022 earnings released: US$6.16 loss per share (vs US$3.78 loss in FY 2021)

Executive VP & Chief Scientific Officer notifies of intention to sell stock

President recently sold US$248k worth of stock

Intellia Therapeutics Presents New Interim Data from First-In-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001

Third quarter 2022 earnings released: US$1.49 loss per share (vs US$0.97 loss in 3Q 2021)

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting

Intellia Therapeutics: Top Speculative Trade In The Biotech Space

Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema

Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling

Intellia Therapeutics, Inc. to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema At the 2022 Bradykinin Symposium

Consensus forecasts updated

Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Intellia Therapeutics down 12% following bottom line Q2 earnings miss

Intellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me Bearish

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announces Additional Positive Interim Data from an Ongoing Phase 1 Study of Their Lead Investigational in Vivo Genome Editing Candidate, NTLA-2001

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022

Intellia Therapeutics: Several Catalysts Expected For H2 2022

Consensus forecasts updated

Price target decreased to US$137

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Intellia Therapeutics, Inc. Names Muna Bhanji to Its Board of Directors

Intellia Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

Price target decreased to US$155

Intellia: One Patent Ruling Turns The Industry Upside Down

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for Treatment of Acute Myeloid Leukemia

Consensus forecasts updated